Neutral charge and hydrophobic nature of these two 1um superparamagnetic beads make them outstanding for in vitro diagnostics (IVD) development, as well as protein isolation and concentration
Dynal has announced the release of Dynabeads MyOne Streptavidin T1 at the AACC meeting in Orlando, Florida.
This bead joins Dynabeads MyOne Tosylactivated, Dynabeads MyOne Carboxylic Acid, and Dynabeads MyOne Streptavidin C1 to strengthen Dynal's in vitro diagnostic (IVD) offering.
These four 1.0um beads are designed to allow the ultimate flexibility for IVD assay design, implementation and automation, while retaining technique uniformity.
The new Dynabeads MyOne Streptavidin T1 are said to show excellent reproducibility and as with Dynabeads MyOne Tosylactivated, are optimised for immunoassays.
The neutral charge and hydrophobic nature of these two beads make them outstanding for IVD development, as well as protein isolation and concentration, says the company.
For example, biotinylated antibodies can be conjugated to Dynabeads MyOne Streptavidin T1 with ease and non-biotinylated antibodies can be coupled directly to Dynabeads MyOne Tosylactivated.
Dynabeads MyOne Carboxylic Acid and the streptavidin pre-coupled version - Dynabeads MyOne Streptavidin C1, are optimised for proteins, peptides and nucleic acids requiring a more negative charge and hydrophilic nature for binding.
Together, these four beads offer very flexible, sensitive and consistent assays, which can be developed and automated with ease.
According to senior international product manager Jack Andreassen, the IVD range has been introduced in response to the variability in both routine and niche testing: "We are proud that Dynabeads has become the benchmark for quality in clinical diagnostics.
"Our customers report that the minimal batch-to-batch variation and chemical flexibility of the IVD Dynabeads means that QC costs and assay development times are reduced, also manufacturing efficiency is increased.
"Now with the smaller 1.0um beads, these benefits are complemented by a decreased sedimentation rate, increased binding capacity, no magnetic remanence and an even quicker response to a magnetic field, making them particularly well suited to automation.
"Their smaller size also produces an increased surface area per gram and therefore an enhanced binding capacity - meaning fewer beads need to be used per assay.
"Again this is a major advantage for automation and we have already received a great deal of interest from assay developers".
Dynal has many years experience in the IVD area and as well as producing the most competent range of off-the-shelf products available, can work closely with diagnostic companies to produce customised magnetic and non-magnetic beads, tailored to highly specific requirements.
Dynal is a pioneer of biomagnetic separation technology and holds the original patents for superparamagnetic beads.
Today, the Dynabeads portfolio supports cell separation for basic and clinical research, genomics, transcriptomics, proteomics, diagnostics and more.
In addition, Dynal offers tailor-made products in collaboration with large volume users.
Dynabeads are superparamagnetic; that is, they exhibit magnetic properties only when placed within a magnetic field and show no residual magnetism when removed from this field.
The polymer shell of the beads protects targets from toxic exposure to iron.
The true uniformity (CV<3%) of size, shape and surface area provides optimal accessibility and reaction kinetics, allowing for rapid and efficient binding.
The true spherical shape and defined surface chemistry minimise chemical agglutination and non-specific binding.
The specific characteristics of the many available bead types facilitate magnetic separation of a wide variety of targets.
Unique batch-to-batch reproducibility (typically within 5%) secures the reproducibility and quality of results.
Separation is gentle and no column or centrifugations are necessary.
